Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal
Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.
New York Magazine16d
The 13 Very Best Long-Sleeved T-shirts for Women
But as with all T-shirts — black, white, or otherwise — the Perfect One often proves elusive. And even though the idea of the “perfect” long-sleeved tee is subjective, that didn’t stop ...
Borsen16d
Zealand-aktien dykker kraftigt – Novo stiger markant
Københavns Fondsbørs har skudt gang i handlen torsdag, hvor C25-indekset åbner stort set fladt med et spinkelt kurshop på 0,4 pct. Pro indhold med dybdegående analyser og nyhedsbreve indenfor finans ...
Forbes16d
The Best Polo Shirts For Men That Are Versatile And Stylish
The best polo shirts for men are comfortable and polished for casual to slightly formal occasions. They’re essentially t-shirts with a collar, making them dressier than a tee but less stuffy ...
The Financial Times18d
Elon Musk’s self-destruction
When Elon Musk said he loved Donald Trump “as much as a straight man can love another”, the emetic effect was widespread. Trump is one of the few people left in Washington DC who likes having ...
pulmonologyadvisor18d
Novo Nordisk Provides Direct-to-Patient Delivery Option for Wegovy
For eligible patients, health care providers can send Wegovy prescriptions directly to NovoCare Pharmacy. Novo Nordisk is providing direct-to-patient delivery of Wegovy ® (semaglutide) through the ...
Finanznachrichten18d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...
Ekstra Bladet18d
Novo Nordisk-aktien falder voldsomt
Novo Nordisk falder mandag formiddag drastisk på den danske børs. Faldet er på 5,3 pct. og sender aktien ned på en pris 566 kr.. Faldet kommer efter, at medicinalgiganten har præsenteret ...
NBC DFW18d
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...
Business Insider18d
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...